RGEN Repligen Corporation

82.24
-1.85  -2%
Previous Close 84.09
Open 83.33
Price To Book 4.1
Market Cap 4,281,319,824
Shares 52,058,850
Volume 230,635
Short Ratio
Av. Daily Volume 685,937
Stock charts supplied by TradingView

NewsSee all news

  1. Repligen Reports Third Quarter 2019 Financial Results and Updates Full Year 2019 Financial Guidance

    Reports quarterly revenue of $69.4 million, representing 40% reported growth and 28% organic growth year-over-yearRaises revenue guidance to $267-$270 million for full year 2019, representing 31%-32% organic growth

  2. Repligen to Report Third Quarter 2019 Financial Results

    WALTHAM, Mass., Oct. 23, 2019 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its third quarter 2019 financial results on Thursday, October 31, 2019. The Company will

  3. Medicenna Strengthens Board of Directors by Appointment of Seasoned Biopharma Executive Ms. Karen Dawes

    Announces Results of Annual Meeting of Shareholders TORONTO and HOUSTON, Sept. 24, 2019 /CNW/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX:MDNA, OTCQB:MDNAF), a clinical stage

  4. Medicenna Strengthens Board of Directors by Appointment of Seasoned Biopharma Executive Ms. Karen Dawes

    Announces Results of Annual Meeting of Shareholders TORONTO and HOUSTON, Sept. 24, 2019 /PRNewswire/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX:MDNA, OTCQB:MDNAF), a clinical

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

CRL received June 22, 2012.
RG1068
Detection of pancreatic duct abnormalities

Latest News

  1. Repligen Reports Third Quarter 2019 Financial Results and Updates Full Year 2019 Financial Guidance

    Reports quarterly revenue of $69.4 million, representing 40% reported growth and 28% organic growth year-over-yearRaises revenue guidance to $267-$270 million for full year 2019, representing 31%-32% organic growth

  2. Repligen to Report Third Quarter 2019 Financial Results

    WALTHAM, Mass., Oct. 23, 2019 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its third quarter 2019 financial results on Thursday, October 31, 2019. The Company will

  3. Medicenna Strengthens Board of Directors by Appointment of Seasoned Biopharma Executive Ms. Karen Dawes

    Announces Results of Annual Meeting of Shareholders TORONTO and HOUSTON, Sept. 24, 2019 /CNW/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX:MDNA, OTCQB:MDNAF), a clinical stage

  4. Medicenna Strengthens Board of Directors by Appointment of Seasoned Biopharma Executive Ms. Karen Dawes

    Announces Results of Annual Meeting of Shareholders TORONTO and HOUSTON, Sept. 24, 2019 /PRNewswire/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX:MDNA, OTCQB:MDNAF), a clinical